Molecular stratification of hospitalized COVID19 patients points to FGFR and SHC4-signaling in ARDS

William Ma[1,*], Antoine Soulé[1,*], Katelyn Yixiu Liu[2], Catherine Allard[3], Salman Qureshi[2], Karine Tremblay[4, †], Simon Rousseau[2, †], and Amin Emad[1, 5, †]

[*] These authors contributed equally.

[1] Department of Electrical and Computer Engineering, McGill University, Montréal, QC, Canada

[2] The Meakins-Christie Laboratories at the Research Institute of the McGill University Heath Centre Research Institute, & Department of Medicine, Faculty of Medicine, McGill University, Montréal, QC, Canada

[3] Statistical department, Centre de recherche du Centre hospitalier universitaire de Sherbrooke (CRCHUS), Sherbrooke, Canada.

[4] Pharmacology-physiology Department, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Saguenay, QC, Canada; Centre intégré universitaire de santé et de services sociaux du Saguenay-Lac-Saint-Jean, Saguenay, QC, Canada; CRCHUS, Sherbrooke, Canada.

[5] Mila, Quebec AI Institute, Montréal, QC, Canada

† Corresponding Authors:
Amin Emad,
755 McConnell Engineering Building, 3480 University Street, Montreal H3A 0E9, Canada
Email: amin.emad@mcgill.ca

Simon Rousseau,
RI-MUHC, E M3.2244, 1001 Décarie, Montréal H4A 3J1, Canada,
Email: simon.rousseau@mcgill.ca

Karine Tremblay,
Pavillon des Augustines, local AUG-5-01A, 225 St-Vallier street, Chicoutimi G7H 7P2, Canada
Email: karine.tremblay@usherbrooke.ca

Abstract

A minority of people infected with SARS-CoV-2 will develop severe COVID-19 disease requiring

invasive respiratory support associated with high mortality. To understand the molecular

mechanisms underlying severe pathology, we conducted an unsupervised stratification of the

circulating proteome that identified six endophenotypes (EPs) among 731 SARS-CoV-2 PCR-

positive hospitalized participants in the Biobanque Québécoise de la COVID-19, with varying

degrees of disease severity and times to intensive care unit (ICU) admission. One endophenotype,

EP6, was associated with a greater proportion of ICU admission, mechanical ventilation, acute

respiratory distress syndrome (ARDS) and death. Clinical features of EP6 included increased levels

of C-reactive protein, D-dimers, elevated neutrophils, and depleted lymphocytes. Proteomic,

metabolomic, and genomic characterization supported a role for neutrophil-associated

procoagulant activity in severe COVID-19 ARDS that is inversely correlated with sphinghosine-1

phosphate plasma levels. Fibroblast Growth Factor Receptor (FGFR) and SH2-containing

transforming protein 4 (SHC4) signaling were identified as molecular features associated with

severe COVID-19. Mechanical ventilation in EP6 was associated with alterations in lipoprotein

metabolism. Importantly, a prognostic model solely based on clinical laboratory measurements

was developed and validated on 631 patients that generalizes the EPs to new patients and creates

new opportunities for automated identification of high-risk groups in the clinic.

Introduction

A minority of people infected with SARS-CoV-2 will develop a severe form of coronavirus disease 2019 (COVID-19) requiring hospitalization and respiratory support. Acute respiratory distress syndrome (ARDS), a condition characterized by the presence of lung inflammation, edema, and impaired gas exchange, is observed in severe COVID-19 and associated with poor survival. Mechanical ventilation is an important critical care management strategy for severe COVID-19 (1). However, during the first waves of the pandemic, almost half of patients undergoing invasive mechanical ventilation died based on case fatality rate reports (2). Defining the molecular mechanisms related to specific severe outcomes, such as ARDS or acute respiratory failure that requires invasive mechanical ventilation, is important to identify treatable traits and improve the survival of critically ill patients.

Successfully reaching this precision medicine goal requires a more granular definition of the underlying pathophysiology. A symptom-based method to discover molecular mechanisms of the disease is inherently confounded by the fact that the same higher-level condition, such as severe COVID-19 disease, can be produced by several different molecular mechanisms, a phenomenon termed the «many-one» limitation (3). Recent advances in computing strategies, such as machine learning, has enabled the development of methods that help overcome this limitation by starting from molecular profiles instead of symptoms to define endophenotypes, *i.e.* subgroups of individuals who are inapparent to traditional classification methods but share a common set of molecular factors that can lead to identification of treatable traits (4-6). Current investigations of endophenotypes in COVID-19 have mainly relied on supervised approaches using fixed outcomes

(such as disease severity) and integrating clinical variables at the onset (7). We hypothesize that

using an unsupervised approach exploiting a rich molecular dataset can provide novel

mechanistic insights into the pathobiology of severe COVID-19 that can help physicians improve

diagnosis, prognosis, and clinical management.

This study identified six endophenotypes linked to diverse clinical trajectories of COVID-19 using

the extensive molecular phenotyping of a cohort of 731 SARS-CoV-2 positive hospitalized patients

from the *Biobanque Québécoise de la COVID-19* (BQC19, www.quebeccovidbiobank.ca) (8), a

prospective observational cohort of SARS-CoV-2-positive and -negative participants recruited in

the province of Québec, Canada, to improve our understanding of COVID-19 pathobiology and

our capacity to alter disease outcomes. The molecular information underpinning these

endophenotypes was used to advance our knowledge of the pathobiology of COVID-19-

associated ARDS.

Results

Unsupervised clustering of SARS-CoV-2-positive hospitalized BQC19 participants reveal endophenotypes associated with varying disease severity and requirements for ventilatory support

In this study, we aimed to identify endophenotypes of COVID-19 based on the circulating proteome of patients in our cohort of SARS-CoV-2 positive hospitalized participants in the BQC19 (Table 1), using an unsupervised approach. Figure S1 shows the distribution of the patient hospital admission dates and the corresponding waves of COVID-19 infection as defined by National Institute of Public Health of Quebec (https://www.inspq.qc.ca/covid-19). For this purpose, we performed consensus agglomerative clustering of the subset of patients (n = 731, Table S1) for whom data corresponding to circulating proteome measured by a multiplex SOMAmer affinity array (Somalogic, ~5,000 aptamers) (9) was available in the BQC19. First, the optimal number of clusters (k = 6) was identified using two criteria, Akaike's Information Criteria (AIC) and Bayesian Information Criteria (BIC) (Figure 1A); then, consensus agglomerative clustering (Euclidean distance and Ward linkage) (10, 11) using 1000 bootstrap subsampling of the patients was performed to obtain six robust clusters (see Methods for details) (Figure 1, Figures S2 and S3). The distribution of Rand-Index, showing the concordance between each one of the 1000 subsampled clusterings and the final consensus clustering is provided in Figure S2B (mean Rand-Index = 0.823), reflecting a high degree of consistency and robustness.

The clinical and pathological characteristics of patients in each endophenotype is provided in Table S1. To characterize the identified endophenotypes (EPs) with respect to disease severity,

we performed two-sided Fisher's exact test to assess their enrichment (or depletion) in "severe"

or "deceased" outcome. EP6 was significantly enriched in the severe/deceased outcomes

(Benjamini-Hochberg false discovery rate (FDR) = 1.72E-18) with either of these outcomes

observed in 66.1% of EP6 patients. Meanwhile, EP1 was significantly depleted in severe/deceased

outcomes (FDR = 8.23E-11) (Figure 2A, Table S1) with either of these outcomes observed in only

11.6% of EP1 patients. In addition, EP6 was enriched in participants 1) receiving oxygen therapy

(FDR = 6.24E-12), 2) receiving ventilatory support (FDR = 6.63E-12), and 3) being admitted to

intensive care unit (ICU) (FDR= 1.26E-22) (Figure 2A, Table S1). Kaplan Meier analysis (12) also

confirmed that the identified EPs have a distinct temporal pattern of admission to ICU

(multivariate logrank test P = 5.06E-36), with EP1 and EP6 having the highest and lowest

probability, respectively, of not being admitted to ICU or dying prior to that in a 40-day span since

their admission to the hospital (Figure 2C). A similar pattern was also observed when patients

that died before admission to ICU were excluded (Figure S4, multivariate logrank test P = 6.55E-

36). A two-sided Mann-Whitney U (MWU) test showed that patients in EP5 were generally older

than other EPs (FDR = 6.94E-5), while EP3 included younger patients (FDR = 1.82E-4). Notably,

EP6 (which had the most severe patients) did not show enrichment in older patients or individuals

with high BMI (two-sided MWU FDR > 0.05) (Figures 2D-F, Table S1).

These analyses revealed that the unsupervised approach using the circulating proteome of the

patients was able to identify endophenotypes with distinct disease characteristics and outcomes.

We identified EP6 as a group of participants with an increase in key measures of COVID-19 disease

severity, including admission to ICU and the need for ventilatory support.

A computational model based on blood markers predicts EPs in a separate validation cohort

To further characterize each EP, we assessed the clinical laboratory results obtained from blood

draws and compared them between the groups. We focused on 21 markers that were measured

in at least 50% of the patients used for consensus clustering (Figure 3A and Table S2) and used

the summary value reported in the BQC19 database corresponding to the most extreme

measurement among multiple blood draws (Table S2). Figure 3A shows the elevation and

depletion of these markers in the identified EPs. EP6 is characterized by abnormal values in

markers of inflammation (lymphopenia, total white blood cell count, neutrophilia, C-reactive

protein (CRP)), liver damage (alanine aminotransferase (ALT)), coagulopathy (D-dimers, low

hemoglobin, International Normalized Ratio (INR), and hyperglycemia (glucose).

Since each EP and particularly EP6, which we identified as the EP with worst outcome, showed a

clear and distinct clinical laboratory result signature compared to other EPs, we sought to develop

a computational prognostic model of disease severity based on these signatures. Due to the

presence of missing values for these markers in our cohort, we developed a nearest-centroid

classifier that is capable of dealing with missing values and can predict EPs based on blood

markers (see Methods for details). To test the prognostic ability of this model on an independent

yet similar dataset, we analyzed 631 SARS-CoV-2 positive hospitalized BQC19 participants that

did not have circulating proteome data and had not been used to identify the endophenotypes.

The clinical and pathological characteristics of patients in each predicted endophenotype (PEP)

are provided in Figure 3B-5E and Table S3.

Our prognostic model identified 116 of these 631 patients as belonging to EP6. Fisher's exact test

showed a significant enrichment of the predicted EP6 (PEP6) in severity/deceased (FDR = 1.77E-

22), while PEP1 and PEP2 were significantly depleted in these outcomes (FDR = 1.61E-4 and FDR

= 1.30E-8, respectively), as shown in Figure 3B and Table S3. Similar to EP6, PEP6 was also

significantly enriched in participants 1) receiving oxygen therapy (FDR = 2.38E-8), 2) receiving

ventilatory support (FDR = 4.40E-8), and 3) being admitted to ICU (FDR = 1.23E-24) (Table S3).

Kaplan Meier analysis also confirmed that these PEPs have a distinct temporal pattern of

admission to ICU (multivariate logrank test P = 1.05E-34), with PEP6 having the lowest chance of

not being admitted to ICU (or dying prior to that) in a 40-day span since their admission to the

hospital (Figure 3E). These results suggest that our prognostic model based on 21 blood markers

can be used to generalize the definition of endophenotypes to patients for whom the proteome

data is unavailable.

In addition to its potential applicability to clinical care, this validation further supports the

relevance of the EP molecular signatures to disease pathogenesis. Therefore, we sought to

improve our understanding of severe COVID-19 using multi-modal molecular and clinical data

associated with each EP, and particularly EP6.

EP6 is enriched among BQC19 participants with acute respiratory distress syndrome

In accordance with increased COVID-19 disease severity, EP6 was also enriched in several medical

complications (two-sided Fisher's exact test) including ARDS (FDR = 1.43E-10), acute kidney injury

(FDR = 6.37E-7), secondary bacterial pneumonia (FDR=2.13E-6), liver dysfunction (FDR = 9.32E-

3), and hyperglycemia (FDR = 1.56E-2) (Figure 4, Table S4). Notably, the frequency of ARDS was

just below 8% in EP1 compared to greater than 44% in EP6, making this complication a key feature

of this endophenotype (Figure 4, Table S4). Therefore, the molecular profiles of EP6 members

could inform the pathobiology of ARDS.

Pathway enrichment analysis identifies FGFR-signaling in severe COVID-19 acute respiratory

distress syndrome

To gain insight into the molecular mechanisms underlying the severity in EP6, we investigated

the aptamers enriched within this endophenotype (Table S5). Consistent with the elevated

neutrophil numbers in EP6, the most enriched aptamer was Cathepsin G, a serine protease

localized in neutrophil azurophil granules. Additionally, we performed pathway enrichment

analysis using the Knowledge Engine for Genomics (KnowEnG) (5). Since aptamers were used to

identify the EPs, it is expected that many of them would have significant associations with the

EPs. As a result, we selected a very strict threshold of FDR < 1E-20 (two-sided MWU test) to

identify top aptamers associated with EP6 (Table S5). We then used the gene set characterization

pipeline of KnowEnG with Reactome pathway collection (13). This analysis showed that EP6 is

characterized by pathways associated with Interleukins and Cytokine Signaling in Immune

system. In addition and in contrast to other EPs, Fibroblast Growth Factor Receptor (FGFR)

signaling was identified in EP6, suggesting this pathway as a potential driver of severe pathology

(Tables 2 and S5).

166 **SHC4 genotype and protein expression levels are associated with higher odds of belonging to**

167 **EP6**

168 To obtain independent support for the involvement of specific proteins identified using

169 aptamers, we leveraged Genome Wide Association Study (GWAS) genotyping data corresponding

170 to these patients. We identified 25 single nucleotide variations (SNVs) distributed in 13 annotated

171 genes that were below a p-value threshold of 1E-4 and distinguished EP6 from the rest (Table 3).

172 We then investigated each of the SNVs to which we could assign a gene and an aptamer, to assess

173 whether their protein product in circulation was differentially regulated by the genotype (Table

174 4). We discovered two genes, *SHC4* (encoding SHC adaptor protein 4) and *CACNA2D3* (encoding

175 calcium voltage-gated channel auxiliary subunit alpha2 delta3) for which there was a significant

176 association between genotype and protein expression levels (p-values < 0.05). While *CACNA2D3*

177 may have mild impact on EP6 membership (odds ratio = 0.61, Table 4), SHC4 was one of the top-

178 enriched aptamers (position 32 out of 4,985) for inclusion in EP6, with an odds ratio of 11.98 for

179 the protein product and 2.00 for the alternate allele, respectively. Therefore, the GWAS analysis

180 revealed that the signaling adaptor protein SHC4 may play an important mechanistic role in

181 contributing to severe disease pathology.

182

183 **EP6 has a distinct metabolomic signature associated with severe COVID-19: low levels of**

184 **sphingosine-1 phosphate are associated with COVID-19 ARDS**

185 To further characterize the pathobiology of severe COVID-19 disease, metabolomic profiling of

186 plasma samples was done in parallel to the SOMAmer analysis. The results yielded data on 1,435

187 metabolites, of which 576 were found significantly altered in EP6 (two-sided MWU FDR < 0.01)

Characterization of the plasma samples supported the distinction among the different EPs at the

levels of metabolomic sub-pathways and individual metabolites (Figure 5 and Table S6). The two

top sub-pathways (FDR < 1E-2) "Methionine, Cysteine, SAM and Taurine Metabolism" and

"phosphatidinylethanolamine (PE)", are known to interact (14, 15) and are associated with pro-

coagulant activities (see Discussion). Strikingly, sphingosine-1 phosphate was enriched in EP1 and

depleted in EP6 (Figure 5B), confirming the previously reported negative association of this

metabolite with COVID-19 ARDS (16). To identify relationships that may shed light on factors

influencing clinical laboratory results that define EP6, we also performed Spearman's rank

correlation analyses between each blood test value and metabolites (Table S2). Finally, to gain

further insight into the potential role of SHC4 in COVID-19 disease severity, we investigated the

metabolites associated with SHC4 in EP6. The only significantly correlated metabolite was 6-

oxopiperidine-2-carboxylate (Spearman's rank correlation = 0.40, FDR = 0.012), where the p-

values were corrected for the number of metabolites using Benjamini-Hochberg FDR.

Mechanical ventilation in EP6 is associated with lipoprotein metabolism

As noted in the introduction, mechanical ventilation in COVID-19 is associated with a high

mortality rate. Within EP6, 55 out of the 118 individuals received mechanical ventilation. Within

all EP6 members that share the overall similar aptamer signature, we identified a subset of

aptamers and metabolites that were significantly different between those with or without

mechanical ventilation (Table 5 and S7). The second most enriched aptamer (Table 5 and S7),

Angiopoietin-like 3 (ANGPTL3), corresponds to a liver-secreted regulator of lipoprotein

metabolism (17), which may reflect alterations observed in fatty acid metabolites (Table S7).

There were no significant differences between the two groups in terms of sex, age, or BMI (Table

S7). Finally, we investigated whether molecular information (proteomic and/or metabolomic)

was associated with mechanical ventilation duration. We identified Alpha-L-iduronidase to be

inversely correlated with duration of ventilation in the patients with mechanical ventilation in

EP6 (Spearman's rank correlation = -0.60, FDR = 2.57E-2, Table S7). Overall, these results point to

an association between altered lipoprotein metabolism and mechanical ventilation in EP6.

Discussion

The results presented herein came from the unsupervised clustering of the circulating proteome

from a large cohort of deeply-phenotyped SARS-CoV-2 positive hospitalized participants. This

broad-based approach has provided both expected and novel findings into the molecular

mechanisms regulating COVID-19. A principal advance is the identification of six COVID-19

disease endophenotypes with different clinical trajectories and distinguishing characteristics that

are summarized in Table 6. One endophenotype, (EP6) was associated with ARDS, the worst

clinical manifestation of COVID-19 that was reflected by a greater proportion of ICU admission,

mechanical ventilation, and severe/fatal outcomes (Figures 2 and 4). Clinical features of this

endophenotype were consistent with published literature including increased levels of CRP, D-

dimers, elevated circulating neutrophils, and reduced peripheral blood lymphocytes (Figure 3A,

Table S2). This information was sufficient to train an accurate prognostic model that could readily

support future clinical care, since it only requires data from routine clinical laboratory results for

prognosis. Our approach also enabled the identification of the following molecular features: 1)

the level of Sphingosine-1 phosphate is highest in EP1 and lowest in EP6, reflecting an inverse

association with time to admission to ICU and/or death; 2) interleukins and FGFR signaling are

molecular pathways associated with severe COVID-19; 3) genetic and environmental

determinants of SHC4 expression are associated with inclusion in EP6; 4) the combined proteomic

and metabolomic signature of EP6 supports a pathologic role for neutrophil-associated

procoagulant activity in COVID-19 ARDS; and 5) mechanical ventilation in EP6 is associated with

altered lipoprotein metabolism.

The approach: unsupervised clustering capacity at identifying clinically meaningful

*subpopulation*s

Our unsupervised clustering approach in conjunction with a rich molecular dataset enabled us to

identify six endophenotypes that could not be captured by simply classifying the population in

two bins solely based on severity. It also provided higher granularity enabling us to uncover

specific associations of molecular factors with blood variables (Table S2) or mechanical

ventilation (Table S7). Accordingly, we identified two endophenotypes with more favorable

outcomes (EP1 and EP2), three endophenotypes with intermediate outcomes in terms of severity

(EP3, EP4 and EP5) and one endophenotype which led to worst outcomes compared to all others

(EP6). In this manuscript, we have focused on the comparison between EP1 and EP6 to highlight

mechanisms of COVID-19-asssociated ARDS. While we have described high level features of EP2-

EP5 in Table 6, further detailed characterization of these other subgroups is ongoing and will be

reported subsequently.

The identification of endophenotypes was done systematically using robust consensus clustering

of aptamer expression levels in which the optimum number of clusters was determined

congruently using two well-established measures: AIC and BIC. The consensus clustering using

bootstrap sampling (1000 times) ensured identification of robust clusters that are not sensitive

to exclusion of some of the samples (20% randomly selected and excluded at each cycle). The

mean Rand-index between each of the 1000 subsampled clusterings and the final consensus

clustering was 0.823, reflecting a high degree of concordance and robustness. Moreover,

identifying the best number of clusters using AIC/BIC (both of which agreed with each other)

allowed us to reveal the patterns of the EPs directly from the data, instead of imposing a pattern

onto it through human supervision. This is an important strength of the study that enabled us to

identify distinct molecular patterns of patients that could have remained undetected using other

traditional approaches.

Additionally, to improve the translational applicability of the EPs, we developed a prognostic

model based only on measurement of conventional clinical laboratory blood markers to test the

generalizability of these endophenotypes to samples without measured aptamer expression

levels. Characteristics of EPs predicted solely based on their blood markers were consistent with

the original EPs, suggesting that clinical blood markers could be used as surrogates for

assignment of these EPs to new patients and potentially automating identification of high-risk

groups in the clinic. This approach takes into account the effect of multiple blood variables

simultaneously and incorporates the full distribution of each variable. This is in contrast to the

clinical laboratory results that are automatically flagged as within or outside normal range, one

variable at a time, therefore increasing the clinical applicability of our model by leveraging a wider

spectrum of information to prognosticate patient outcomes.

COVID-19 ARDS molecular pathology: a counterbalance between ceramides and sphingosine is

associated with critical illness.

The datasets used in this study carry rich molecular information on mechanisms of disease for

COVID-19. EP6 is characterized by its enrichment in ARDS (44% vs 8% in EP1, Figure 4), acute

kidney injury (45%) and liver dysfunction (19%) (Table S4). Low levels of Sphingosine 1-phosphate

(S1P) are associated with ARDS and were shown to be associated with greater ICU admission and

decreased survival in COVID-19 (16). Accordingly, we found that S1P levels are depleted in EP6

while they are enriched in EP1 (Figure 5B). Interestingly, the aptamer detecting neutral

ceramidase, an enzyme converting ceramides into sphingosine, is enriched in EP1 (FDR = 2.65E-

10, Table S5). While changes in protein abundance as detected by aptamers may not necessarily

reflect changes in enzymatic activity, it is interesting to note that dihydroceramides and

ceramides are depleted in EP1 (Table S6). Conversely, dihydroceramides and ceramides are

significantly enriched in EP6 (Table S6), suggesting that there is a shunting of the pathway away

from sphingosine towards more pro-inflammatory ceramides that are associated with metabolic

disorders (18). Moreover, one of the top aptamers found enriched in EP6 (FDR = 2.10E-56, Table

S5) is serine palmitoyltransferase 2 (SPTLC2), an enzyme that is responsible for the rate-limiting

step in *de novo* sphingolipid biosynthesis (19, 20). These results suggest a counterbalance

between ceramides and sphingosine, where the former is associated with poorer outcomes

during critical illness, whereas higher levels of the latter is associated with more favorable

outcomes in ARDS.

Multimodal profiling of EP6 supports a role for neutrophil-derived procoagulant activity-mediated

organ damage in COVID-19.

COVID-19 ARDS was found to be more frequently associated with thrombotic complications than

non-COVID-19 ARDS (21, 22). In addition, histopathologic evidence of pulmonary microthrombi

is frequently observed in autopsies of individuals deceased with COVID-19 (23). Early reports

suggested a role for neutrophil-mediated release of NETs contributing to endothelial dysfunction

as a mechanism of microthrombosis in COVID-19 ARDS (24-35). Cathepsin G, a neutrophil-derived

serine protease (serprocidin), is the top-enriched aptamer in EP6 (FDR = 4.10E-58, Table S5).

Notably, two other serprocidins, neutrophil elastase and proteinase-3, are also significantly

enriched in EP6 (FDR = 1.04E-10 and FDR = 8.27E-7, respectively). In addition to their roles in

bacterial killing, serprocidins couple innate immunity to coagulation, where they promote

coagulation by enhancing tissue factor and factor XII-dependent coagulation (36). Serprocidins

are also important regulators of NETosis (37). In pediatric sepsis, another NETosis-associated

protein Olfactomedin 4 (OLFM4) (38) is associated with increased odds of having greater organ

failure and death (39). In accordance with these findings, OLFM4 is greatly enriched in EP6 (top

5%; FDR = 2.61E-46, Table S5). Collectively, these findings point to enhanced neutrophil-derived

procoagulant activity in EP6 in response to SARS-CoV-2 infection that is associated with worse

outcomes.

The procoagulant environment associated with COVID-19-associated organ damage is further

supported by the alteration in metabolic profiles in EP6. "Methionine, Cysteine, SAM and Taurine

Metabolism" and "phosphatidinylethanolamine (PE)" (Figure 5, Table S6) are two sub-pathways

known to interact (14), with PE methylation acting as a major consumer of S-Adenosylmethionine

(SAM) leading to the synthesis of S-Adenosylhomocysteine (SAH) and cystathionine (15), which

itself has been found upstream of 2-hydroxybutyrate and 2-aminobutyrate in a model of

hepatoxicity (40). SAH, cysthathionine, 2-hydroxybutyrate and 2-aminobutyrate are all

significantly enriched in EP6, and this group also exhibits a higher rate (FDR < 1E-2) of liver

dysfunction (Figure 4, Table S4), with significant abnormalities in several relevant clinical blood

markers including ALT, albumin, bilirubin and LDH (Figure 3A, Table S2). PEs become exposed at

the surface of cell membranes upon exposure to stress, inflammation, and cell death (41, 42). In

a Syrian hamster model, infection with SARS-CoV-2 markedly increased circulating PE expression

in the animals that were fed a high salt, high fat diet, demonstrating the interaction between

infection and metabolic disorder (43). Furthermore, the membranes of azurophilic granules,

which contain serprocidins, are enriched in PE (44). Accordingly, the significantly enhanced PE

abundance in EP6 is associated with decreased platelet counts, increased D-Dimers, INR and

activated partial thromboplastin time (aPTT) (Figure 3A, Table S2), hallmarks of abnormally

activated coagulation pathways that are associated with serious and often lethal complication of

sepsis (45). Taken together, the metabolomic profile of EP6 is associated with increased

circulating pro-coagulant activity that can be linked to organ damage, with notable enrichment

in liver damage and acute kidney injury in the cluster (Figure 4). Recent results from the

Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC) study showed

anticoagulation to be efficacious in moderate but not severe COVID-19 disease (46, 47), revealing

a need for alternative management approaches in critically ill patients.

Tryptophan and polyamine metabolism in COVID-19 acute kidney injury

Altered kynurenine levels following SARS-CoV-2 infection have been shown to be associated with

increased IL-6 expression and kidney injury (48). Interestingly, we also observed kynurenine to

be enriched in EP6 but depleted in EP1, supporting the association of increased kynurenine with

COVID-19 severity and higher incidence of acute kidney injury. Spermidine/spermine N(1)-

acetyltransferase (SSAT) contributes to polyamine synthesis and its extracellular metabolite, N1,

N12-diacetylspermine, is one of the top 15 metabolites enriched in EP6 (Figure 5B). N1, N12-

diacetylspermine is positively correlated with urea and creatinine is negatively correlated with

lymphocyte numbers (Table S2). Deletion of SSAT in mice is protective against LPS-induced kidney

injury (49), and SSAT activity is associated with an increased white blood cell count in acute and

chronic myeloid leukemia patients (50). Taken together, these observations suggest that the

tryptophan and polyamine metabolites are associated with acute kidney injury in COVID-19 and

identifies another potential pathway of disease progression leading to organ damage.

Novel molecular markers of COVID-19 pathology: FGFR and SHC4

Two novel molecular factors associated with COVID-19 ARDS that were identified by our study

are FGFR and SHC4. Circulating levels of the pro-angiogenic FGF-2 has been associated with

COVID-19 severity and creatinine levels in a study of 208 SARS-CoV-2 positive participants (51).

It is also noteworthy that the use of Nintedanib, an inhibitor of FGFR, Vascular Endothelial Growth

Factor Receptor (VEGFR) and Platelet-Derived Growth Factor Receptor (PDGF-R) that is approved

for use in interstitial lung disease, improved pulmonary inflammation and helped three middle-

aged obese COVID-19 patients with markedly impaired lung function wean off mechanical

ventilation (52). While the adaptor protein SHC4 has not been experimentally demonstrated to

modulate FGFR signaling, a 12-gene biomarker signature associated with melanoma contains

FGFR2, FGFR3 and SHC4 (53). It is attractive to speculate that SHC4 may act downstream of FGFR

or other associated growth factor receptors, favoring heightened procoagulant activity

associated with COVID-19 ARDS. In view of the limited knowledge of this understudied member

of the SHC family, we looked at the metabolites associated with SHC4 to gain insights into its

possible functions. Interestingly, 6-oxopiperidine-2-carboxylate (the only metabolite with a

significant correlation with SHC4 in EP6) was found to be negatively associated with glomerular

filtration rate in a GWAS study of kidney disease and hypertension in African-Americans (54).

Acute kidney injury is a frequent complication of acute liver failure (55), and liver dysfunction is

associated with abnormal coagulation (56). Thus, the overall molecular information coming from

the multi-modal analysis of EP6 points to a triad between liver function, kidney function and

hemostasis that becomes dysfunctional following ARDS-associated inflammation driven by SARS-

CoV-2 infection. Whether the presence of SHC4 in circulation is a marker of dysfunction of this

triad, or an active mediator remains to be determined. Moreover, the identity of the cells

expressing SHC4 leading to its presence in the circulation is not known. Taken together, our

identification of FGFR and SHC4 signaling pathways distinguishing EP6 from other

endophenotypes provides a rationale for investigation of their potential utility as biomarkers of

severe disease activity and/or the use of antagonists of those pathways to treat severe COVID-

19 disease manifestations.

Molecular mechanisms of mechanical ventilation in EP6: a potential role for ANGPTL3

ANGPTL3 is a liver-secreted enzyme that can inhibit lipoprotein and endothelial lipase (57). Loss-

of-function of ANGPTL3 is associated with hypolipidemia (58). Therefore, increased circulating

levels of ANGPTL3 would be expected to raise plasma levels of triglycerides and phospholipids,

which is consistent with the observed metabolomic profiles (Table S7). Whether these alterations

are sufficient to increase the likelihood of mechanical ventilation remains speculative.

Nevertheless, it is interesting to note that administration of medium- and long-chain triglycerides

can aggravate gas exchange abnormalities in ARDS (59) and may warrant the preclinical

investigation of ANGTPL3 antagonists like Evinacumab or other functionally similar therapeutic

agents (60) to ameliorate outcomes in ARDS. As for the duration of mechanical ventilation, we

discovered an inverse correlation with alpha-L-iduronidase (IDUA), a lysosomal enzyme required

for the degradation of heparan sulphate and dermatan sulphate (61). Our current data cannot

distinguish between the presence of this enzyme as a biomarker or as an active mediator that

influences the course of COVID-19-associated acute respiratory failure.

Limitations and considerations

The data presented in this study come from individuals participating in the BQC19, a prospective

observational cohort built to study COVID-19 in Québec (Canada) with its specific population

profile as reported previously (8). A chronological bias may also be present, as most of the

participants used for endophenotyping in this study were recruited during the first two waves of

the pandemic (Figure S1), prior to widespread vaccination in Québec and the appearance of the

Omicron variant and sub-variants. Therefore, some of the features of the identified

endophenotypes may change over the course of the pandemic. It will be essential to continue

longitudinal assessments of the molecular profiles to better understand the dynamic nature of

host-pathogen interactions. It will also be interesting to compare the profiles of COVID-19 ARDS

to other viral-induced ARDS, to identify common as well as distinguishing features of these

conditions.

In this study, we used circulating proteome as determined by aptamers to identify

endophenotypes, a task for which it is well suited as it can capture a dynamic landscape.

However, several important considerations need to be mentioned when using this approach.

First, raw (unnormalized) expression values of the same aptamer can be used to compare

different samples, but these values cannot be used to compare different aptamers against each

other in the same sample, since they only show the relative abundance of expression and not

absolute expression. As such, one needs to first normalize these values across samples (one

aptamer at a time) and then subject them to follow-up analysis such as clustering as we have

done in this study. Second, since information only shows relative abundance, focusing on an

individual aptamer and analyzing its absolute abundance will require additional measurements.

Moreover, to analyze aptamers individually (instead of the collective approach that we used in

this study), one must consider the effect of complexes and non-specific binding that may result

in noisy data. As such, we favored collective analysis of the aptamer expression data after proper

normalization, which enabled us to identify various EPs and important molecular mechanisms

discussed in this study.

Future directions

There is enormous amount of data within this study and BQC19 that could be exploited by the

scientific and medical community to improve our understanding of COVID-19 and novel emerging

acute respiratory illnesses. Analyzing the molecular profiles of the other EPs, in particular EP3-5,

which led to similar outcomes from distinct molecular pathways (Table 6) in more detail should

further yield important insights into mechanisms of the disease. For example, EP5 is enriched in

males and cardiovascular disease complications, while EP4 is enriched in females (like EP1), yet

both of these groups exhibit different distinct clinical trajectories that point to sex-dependent

and additional sex-independent mechanisms of disease.

Conclusion

The major strength of this study is the use of an unsupervised approach for analysis of a large

and deeply phenotyped cohort. We showed that this strategy can address both fundamental

scientific questions pertaining to mechanisms of disease and help the medical community

improve clinical outcomes through early identification of patients that may experience a severe

clinical course during COVID-19 infection.

Methods:

Datasets and preprocessing

The Biobanque Québécoise de la COVID-19 (BQC19; www.quebeccovidbiobank.ca) is aimed at

coordinating the collection of patients' data and samples for COVID-19 related research. Data

and samples were collected from ten sites across the province of Québec (Canada) (8). BQC19

organizes the collected data, including clinical information and multi-omics experimental data,

before making it available in successive releases. For this study, we used release #5 of the clinical

data published in December 2021, the circulating proteome determined using SOMAmers and

Metabolomics data (62). BQC19 GWAS imputation data was generated by Tomoko Nakanishi at

Brent Richards lab, Jewish General Hospital and McGill University. Detailed codes used for

generating the data can be found in: https://github.com/richardslab/BQC19_genotype_pipeline.

Our main corpus of analysis consisted of n = 1,362 hospitalized and SARS-CoV-2 positive patients

(based on qRT-PCR) of BQC19. This included n = 731 patients for which both clinical and

proteomic data were available as well as n = 631 patients for which proteomic data was not

available, but their clinical data contained measurements for more than half (at least 11 out of

21) of the blood markers that we used as a validation set for the prognostic model developed in

this study.

We also obtained data (n = 731) corresponding to the circulating proteome measured between

April 2, 2020 and April 20, 2021 by a multiplex SOMAmer affinity array (Somalogic, 4,985

aptamers) from BQC19 (release #3 Sep. 2021, associated patients' data updated in release #5

Dec. 2021). When measurements of the same patients but at different time points were

available, we used the one corresponding to the first time point. SomaScan is a biotechnological

protocol commercialized by the Somalogic company (9). It relies on a set of artificial aptamers

linked to a fluorophore and each designed to bind a single protein. Once added to the sample,

the activity of each aptamer is measured through fluorescence and used to approximate the

expression level of the targeted protein. SomaScan protocol comprises several levels of

calibration and normalization to correct technical biases. Log2 and Z-score normalization were

performed on each aptamer separately in addition to the manufacturer's provided normalized

data (hybridization control normalization, intraplate median signal normalization, and median

signal normalization). Since the data was analyzed by Somalogic in two separate batches, we

applied the z-score transformation separately to each batch, to reduce batch effects. These

additional transformations ensure that the measured values of different aptamers are

comparable and can be used in cluster analysis.

We obtained metabolomic data (1,435 metabolites) from BQC19. We used the batch-normalized,

missing values imputed and log-transformed version of the data.

Analyses of the GWAS dataset

For the GWAS analyses, annotation of SNVs were done using the biomaRt package (63) from R

(64) and all analyses were done using R version 4.1.3. Quality control steps were derived in

majority from a 2017 QC tutorial article (65). At the beginning, we had 867,450 markers and 2,429

samples. We import Plink format data into R using the "read_plink" function from genio package

(66) from R. We removed 103,592 non ACGT bi-allelic markers. We calculated the predicted sex

by looking at the rate of homozygote markers on chromosome 23. We removed 3,588 markers

with call rates < 98%, 448,932 monomorphic markers and markers with MAF <0.05, and 28,092

markers with Hardy Weinberg equilibrium < 1E-6 (calculated by the "HWE.exact" function from

the genetics package (67) from R. For the EP6 cluster group analyses, we removed in addition

1,747 samples that were not in the cluster analysis, 8 samples with a sex discrepancy (based on

predicted sex calculated earlier and reported sex), and 3 samples with a heterozygosity rate > 3

standard deviations. We finally removed a pair of samples who had approximately the same

genome probably due to an error of manipulation. We couldn't know which one was the right

sample, so we removed both of them. We also had 2 pairs of individuals who had a pi-hat of ~0.5

(meaning first degree relatives), we decided to keep one sample per pair, the one with the higher

call rate. All other pairs of individuals had a pi-hat < 0.21 that is judge acceptable considering our

population. Pi-hat were calculated with the "snpgdsIBDMoM" function from SNPRelate package

(68) from R. At the end of quality controls, 283,246 markers on 655 samples have been used to

perform association analyses.

To perform the principal component analyses (PCA), we took a subsample of independent

markers (pruning) with a maximum sliding window of 500,000 base pairs and a linkage

disequilibrium (LD) threshold of 0.2 using the "snpgdsLDpruning" function from the SNPRelate

package from R. We ran the PCA with the "snpgdsPCA" function from SNPRelate package from

R. The first 2 principal components (PCs) were considered significant.

For the GWAS analyses of the 283,246 remaining markers between EP6 cluster compared to all

others, we modeled a logistic regression with the dichotomous variable indicating if the

participants belong to the EP6 cluster as the outcome variable. We used the additive model for

markers as an independent variable and we adjusted the models with the first two PCs. Odds

ratio and p-values were calculated on each model. QQ-plots have been performed as quality

control of the models; p-values were plotted using "qqplot.pvalues" function from gaston

package (69) from R (data not shown). We compared the aptamers' normalized level of

expression (based on normalization described earlier) between the three groups of genotypes

for each studied genes by performing standard ANOVA analyses followed by Tukey *post hoc* tests

(referred to in this study as pQTL analysis). Since aptamers tested are limited compared to the

SNVs, we have fixed significance p-values threshold below 1E-4 to report more SNVs instead of

the more common 1E-5 suggestive threshold. Finally, to identify if the cluster EP6 may be

explained by the aptamers and the SNVs, we performed multiple logistic regression analyses

models include aptamers expression values, SNV genotypes (additive model) and the two

principal components. OR are reported with 95% confidence intervals.

Consensus agglomerative clustering

Patients were clustered using agglomerative clustering, with Euclidean distance and Ward's

linkage (10, 11). To identify number of clusters k, we used the elbow method based on the Akaike

Information Criterion (AIC) and Bayesian Information Criterion (BIC). More specifically, we

calculated the AIC and BIC for clustering using k = 2, 3, …, 20 and used the Kneedle algorithm (70)

to identify the value of k corresponding to the "elbow", where increasing the value of k does not

provide much better modeling of the data. Kneedle identified k = 6 as the number of clusters

based on both AIC and BIC (Figure 1A).

Given the number of clusters in the data, we then used consensus clustering with sub-sampling

to obtain robust endophenotypes. We randomly sampled 80% of the patients 1000 times. Each

time, we used agglomerative clustering above with k = 6 to identify clusters. Given these 1000

clusterings, we calculated the frequency of two patients appearing in the same cluster, when

both were present in the randomly formed dataset. We then performed one final agglomerative

clustering of these frequency scores to identify the six endophenotypes (Figure S2A and Figure

1B).

Metabolomic pathway characterization of EP6

The 1435 metabolites measured were organized into 122 sub-pathways in the original dataset

(denoted as "SUB_PATHWAYS"). We first identified metabolites whose values were significantly

higher or lower in EP6 compared to other EPs (two-sided MWU test, FDR<0.01). Then, we used

these metabolites to perform pathway enrichment analysis (one-sided Fisher's exact test) based

on 122 pathways. The resulting p-values (Table S6) were then corrected for multiple tests using

Benjamini-Hochberg FDR.

Nearest-centroid predictor based on blood markers

In order to predict endophenotypes from blood tests, we developed a missing-value resilient

nearest-centroid classifier. We used the set of patients that were used to form the original EPs

(n = 731) as the training set and the set of patients that did not have proteome data as the

validation set (n = 631). First, we z-score normalized each blood marker across all the patients in

the training set, one marker at a time. We then formed a blood marker signature (a vector of

length 21) for each EP. Each element of an EP's signature corresponds to the mean of the

corresponding marker across all patients of that EP.

To predict the EP label of each patient in the test set, we first z-score normalized their blood

marker measurements using the mean and standard deviation of the blood markers calculated

from the training set. Then, we calculated the cosine distance between each test patient's blood

marker profile and the centroids (excluding missing values) and identified the nearest EP as the

predicted EP (PEP) label of the patient.

Statistics

Several non-parametric tests, including Mann Whitney U test, Fisher's exact test, and Spearman's

rank correlation, were used in this study. Benjamini-Hochberg false discovery rate (FDR) was used

to adjust the p-values for multiple tests. Details of statistical tests were discussed where they

were used.

Study approval

The study was approved by the Institutional Ethics Review Board of the "Centre intégré

universitaire de santé et de services sociaux du Saguenay-Lac-Saint-Jean" (CIUSSS-SLSJ) affiliated

to Université de Sherbrooke [protocol #2021-369, 2021-014 CMDO – COVID19].

Acknowledgements

This work was made possible through open sharing of data and samples from the Biobanque

Québécoise de la COVID-19, funded by the Fonds de recherche du Québec - Santé, Génome

Québec, the Public Health Agency of Canada and, as of March 2022, the Ministère de la Santé et

des Services Sociaux du Québec. We thank all participants to BQC19 for their contribution. This

study was supported by the Fonds de recherche du Québec - Santé (FRQS)- Cardiometabolic

Health, Diabetes and Obesity Research Network (CMDO)- Initiative. This work was also supported

by Natural Sciences and Engineering Research Council of Canada (NSERC) grant RGPIN-2019-

04460 (AE).

Conflict of Interests

The authors have declared that no conflict of interest exists.

Figures

Figure 1: Unsupervised consensus clustering of SARS-CoV-2 positive patients.
A) The elbow points (circles in red) of Akaike's Information Criteria (AIC) and Bayesian Information Criteria (BIC) curves versus number of clusters consistently corresponded to k=6 as the optimal number of clusters. B) The heatmap shows the expression of aptamers (rows) in each sample (columns). The dendrogram shows the identified endophenotypes. C) Characterization of samples based on sex at birth, highest world health organization (WHO) severity level achieved, intensive care unit (ICU) admission, ventilatory support, and oxygen therapy. For the last three rows, a sample colored "black" reflects a label of "yes".

Figure 2: Characterization of endophenotypes (EPs).
A) Enrichment or depletion of each EP in clinical variables (one cluster versus rest). Two-sided
Fisher's exact tests are used to calculate the p-values, which are corrected for multiple tests using
Benjamini-Hochberg false discovery rate (FDR). Gradients of blue show depletion, while gradients
of red show enrichment. FDR values above 0.05 are depicted as white. B) The number of patients
in each EP and the colors used to represent them in panels C, D, and E. C) Kaplan-Meier analysis
of the time between patients' admission to the hospital and their admission to intensive care unit
(ICU) (or death if earlier) for each EP (Delta). D) Distribution of age in each EP. E) Distribution of
BMI in each EP. F) COVID-19 severity in each EP.

Figure 3: Differential expression patterns of blood markers in the identified endophenotypes (EPs) and characterization of predicted endophenotypes (PEPs) based on the prognostic model. A) Heatmaps of false discovery rates (FDR) values for two-sided one-vs-rest Mann–Whitney U tests for 21 blood markers for each EP. Abbreviations used: WBC = white blood cells, LDH = lactate deshydrogenase, ALT = alanine aminotransferase, aPTT = activated partial thromboplastin time, INR = International Normalized Ratio. FDR values below 0.05 are shown as white. B) World health organization COVID-19 severity assessed in each PEP. C) Distribution of age in each PEP. D) Distribution of BMI in each PEP. E) Kaplan-Meier analysis of the time between patients' admission to the hospital and their admission to ICU (or death if earlier) for each PEP (Delta). The colormap

622   in panel E shows the number of patients in each PEP group and the colors used to represent them
623   in panels C, D, and E. PEPs were predicted based on blood markers and were not used to originally
624   identify the EPs.

630
631   **Figure 4:** Frequency and significance of complications in different EPs.
632   The value in each cell shows the percentage of patients of that EP (column) that suffered from
633   the complication (row). The colors represent two-sided Fisher's exact test false discovery rate
634   (FDR, corrected for multiple tests). Red represents enrichment, while blue represents depletion.
635   FDR values below 0.05 are shown as white.
636

637
Figure 5: Metabolite characteristics of endophenotypes (EPs).

A) The heatmap shows the enrichment (one-sided Fisher's exact test) of EPs in different metabolite sub-pathways. See Table S6 for the full list. B) The heatmap shows the over-expression (red) and under-expression (blue) of metabolites in different EPs (two-sided Mann–Whitney U test). Row names show metabolites followed by the sub-pathway to which they belong in parentheses. Only top 15 metabolites (based on false discovery rate for EP6) for which a definite name and sub-pathway are available are shown. Full list is provided in Table S6.

645   **Tables**

646   **Table 1:** Clinical and pathological characteristics of the BQC19's participants used in this study.

		Cohort (n = 1,362) No. (%)
Age in years	<45	17.5
	45-65	33.6
	>65	48.7
	Unknown	0.3
Body mass index in kg/m²	<20	3.8
	20-25	13.0
	25-35	27.8
	>35	7.4
	Unknow	47.9
Sex at birth	Female	44.8
	Male	55.2
Severity	Dead	4.4
	Severe	21.8
	Moderate	51.0
	Mild	11.8
	Unknown	10.9
Oxygen therapy	Yes	48.2
	No	21.0
	Unknown	30.8
Ventilatory support	Yes	47.6
	No	14.0
	Unknown	38.5
Admission to intensive care unit	Yes	17.5
	No	33.6
	Unknown	48.7

647
648

649 **Table 2:** Reactome pathways associated with EP6, based on expression of aptamers. KnowEnG
650 analytical platform was used. The p-values were calculated using a one-sided Fisher's exact test
651 and were corrected for multiple tests using Benjamini-Hochberg method. Only signaling
652 pathways with FDR<5E-4 are shown in this table (see Table S5 for the full list).
653

Pathway	FDR
Signaling by Interleukins	2.75E-12
Cytokine Signaling in Immune system	6.25E-10
Immune System	2.28E-06
Signaling by FGFR	4.75E-06
Constitutive Signaling by Aberrant PI3K in Cancer	2.94E-05
FGFR2 ligand binding and activation	5.77E-05
Extracellular matrix organization	1.85E-04
FGFR3 ligand binding and activation	1.85E-04
FGFR3c ligand binding and activation	1.85E-04
FGFRL1 modulation of FGFR1 signaling	1.85E-04
TNFs bind their physiological receptors	2.58E-04
PI3K/AKT Signaling in Cancer	3.28E-04
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	4.14E-04
Interleukin-4 and 13 signaling	4.91E-04

654
655

656 **Table 3**: SNVs differentiating EP6 against all other endophenotype clusters.

SNV ID	Position	Gene Symbol	SNV [1]	MAF	HWE	OR [2]	p-value
rs1394671	chr5:7348567	-	G > A	0.240	0.095	2.28	2.41E-06
rs12186698	chr5:168880668	*SLIT3*	T > C	0.087	0.247	2.93	3.72E-06
rs11625406	chr14:50049474	-	C > A	0.438	0.137	0.47	1.03E-05
rs11862889	chr16:83828886	-	T > C	0.104	0.446	2.62	1.07E-05
rs2995918	chr4:37905775	*TBC1D1*	C > T	0.494	0.776	0.49	1.20E-05
rs16897810	chr5:68415296	-	G > A	0.093	0.001	2.67	1.43E-05
rs2376263	chr17:35436659	*SLFN13*	G > A	0.261	0.073	2.01	2.48E-05
rs4790712	chr17:1614620	*SLC43A2*	G > A	0.441	0.003	1.97	2.50E-05
rs2294566	chr20:41472939	*CHD6*	C > A	0.239	0.265	2.04	2.78E-05
rs7164451	chr15:48921859	*SHC4*	G > A	0.386	0.053	1.89	3.01E-05
rs57664621	chr8:22808443	*PEBP4*	G > C	0.174	0.016	2.16	3.07E-05
rs28482919	chr3:14903094	*FGD5*	T > C	0.187	0.053	0.32	3.20E-05
rs6559283	chr9:89712560	-	T > C	0.375	<0.001	1.96	3.27E-05
rs657075	chr5:132094425	-	A > G	0.104	0.328	2.49	4.28E-05
rs56235109	chr15:62424001	*TLN2*	A > G	0.235	0.366	0.38	4.67E-05
rs7620057	chr3:179473377	*GNB4*	T > C	0.099	1.000	2.51	4.67E-05
rs10466868	chr12:131455375	-	T > G	0.108	0.401	2.51	5.94E-05
rs2236798	chr1:18735127	*PAX7*	A > G	0.054	0.114	2.90	6.11E-05
rs3774814	chr4:5464702	*STK32B*	C > G	0.205	<0.001	0.36	6.75E-05
rs4497815	chr19:22903215	-	G > A	0.216	0.205	2.07	7.52E-05
rs6765694	chr3:54601810	*CACNA2D3*	G > A	0.404	0.833	0.51	7.66E-05
rs2797773	chr6:37559045	-	C > T	0.422	0.000	0.53	8.06E-05
rs17014760	chr4:129419725	-	A > A	0.316	0.000	1.89	9.33E-05
rs10948260	chr6:45835559	-	G > A	0.366	0.189	1.81	9.52E-05
rs12035677	chr1:232391209	-	A > G	0.063	0.000	3.02	9.95E-05

657 Abbreviations used: SNV = Single nucleotide variation, HWE = Hardy Weinberg Equilibrium, MAF
658 = Minor allele frequency, OR = Odd ratio.
659
660 [1] SNV are described following GWAS annotations: refence allele > alternative allele (e.g., G > A).
661 [2] Logistic regression analyses using additive model adjusted for the 2 principal components.
662

663 **Table 4:** Association between genotypes and aptamer expression levels

SNV	Gene Symbol	Nearest gene	Aptamers normalized expression [1]				Multiple logistic regression analyses [3]			
			HM_{ref}	HTZ	HM_{alt}	p-val [2]	Aptamers OR	p-val	SNV OR	p-val
rs6765694	*CACNA2D3*	-	-0.09 (±0.89)	0.01 (±1.10)	0.24 * (±0.99)	**0.011**	0.61 (0.46-0.79)	2.5E-4	0.52 (0.37-0.74)	2.4E-4
rs10948260	-	*CLIC5*	0.02 (±0.92)	0.02 (±1.09)	-0.02 (±0.97)	0.796	0.68 (0.55-0.83)	1.7E-4	1.83 (1.35-2.48)	8.8E-5
rs657075	-	*IL3*	-0.01 (±1.01)	0.05 (±0.99)	0.32 (±0.46)	0.328	1.37 (1.14-11.64)	8.2E-4	2.49 (1.60-3.88)	5.2E-5
rs7164451	*SHC4*	-	-0.07 (±0.90)	0.01 (±1.05)	0.23 * (±1.16)	**0.017**	11.98 (7.61-18.87)	8.4E-27	2.00 (1.30-3.09)	1.8E-3
rs12186698	*SLIT3*	-	0.00 (±1.02)	0.07 (±1.06)	0.15 (±0.89)	0.509	0.82 (0.64-1.06)	0.135	2.99 (1.89-4.73)	2.7E-6
rs56235109	*TLN2*	-	-0.03 (±0.98)	0.06 (±1.03)	0.04 (±1.27)	0.353	0.58 (0.45-0.75)	2.7E-5	0.38 (0.23-0.60)	4.7E-5

664 Abbreviations used: SNV = Single nucleotide variation, HM_{ref} = Homozygotes for the reference
665 allele, HM_{alt} = Homozygotes for the alternative allele, HTZ = Heterozygotes, OR = Odd ratio.
666
[1] Aptamers' normalized levels of expression are reported as mean (± standard deviation).
Normalization steps for aptamer expressions are described in Methods.
[2] p-value, standard ANOVA analyses followed by Tukey *post hoc* analyses. Asterisks (*) identify
difference between HM_{ref} and HM_{alt} genotypes.
[3] Multiple logistic regression analyses models include aptamers expression values, SNV
genotypes (additive model) and the two principal components. OR are reported with 95%
confidence intervals in parentheses.
674

Table 5: Aptamers associated with mechanical ventilation in EP6.
In this table, p-values are obtained using a two-sided Mann Whitney U test and is corrected for
multiple tests using Benjamini Hochberg FDR. A value of +1 (-1) in the "sign" column shows that
the value of aptamer was higher (lower) in the samples of 55 patients that received mechanical
ventilation in EP6, compared to the rest of EP6 members. Only 14 targets with FDR < 1.2E-02 are
shown. The full list is provided in Table S7.
681

Target	Target Full Name	p-values	FDR	Direction
GGE2D	G antigen 2D	2.93E-08	1.46E-04	+1
ANGPTL3	Angiopoietin-related protein 3	2.76E-06	4.58E-03	+1
Luteinizing hormone	Luteinizing hormone	2.55E-06	4.58E-03	-1
CRBS	Beta-crystallin S	1.01E-05	8.37E-03	-1
NCAM-120	Neural cell adhesion molecule 1; 120 kDa isoform	8.78E-06	8.37E-03	-1
SIA10	Type 2 lactosamine alpha-2;3-sialyltransferase	7.36E-06	8.37E-03	-1
LRP1	Prolow-density lipoprotein receptor-related protein 1	2.77E-05	1.16E-02	-1
CLM2	CMRF35-like molecule 2	2.70E-05	1.16E-02	-1
THS7A	Thrombospondin type-1 domain-containing protein 7A	1.65E-05	1.16E-02	-1
LAP	Cytosol aminopeptidase	3.04E-05	1.16E-02	-1
CXCL16	C-X-C motif chemokine 16	2.64E-05	1.16E-02	+1
FSH	Follicle stimulating hormone	2.52E-05	1.16E-02	-1
VEGF sR2	Vascular endothelial growth factor receptor 2	3.27E-05	1.16E-02	-1
ASGR1	Asialoglycoprotein receptor 1	2.97E-05	1.16E-02	+1

682
683
684

685 **Table 6:** Summary of the characteristics of each endophenotype.
686 In this table, High (Low), denoted as H (L) implies that the average value of the variable in the
687 corresponding EP was significantly higher (lower) than the other EPs (considered together), while
688 N (Nondescript) implies that it was not significantly different. The table is formed based on results
689 described in Tables S1, S6 and S2.

Endophenotype	Age	Sex at birth	BMI	Metabolic sub-pathways	Blood markers
EP1	H	F	N	Leucine, Isoleucine and Valine Metabolism	High lymphocyte, Low neutrophil
EP2	N	N	L	N	High albumin, Low white blood cells
EP3	L	M	N	Phospholipid Metabolism	High platelet, Low creatinine
EP4	N	N	N	Ascorbate and Aldarate Metabolism	High lactate deshydrogenase
EP5	H	N	N	Benzoate Metabolism	High creatinine, Low haemoglobin
EP6	N	M	N	Methionine, Cysteine, SAM and Taurine Metabolism	High white blood cells, Low lymphocyte

690 Abbreviations used: H = High, L = Low, N = Nondescript, F = Female, M = Male
691

References

692   **References**

693   1.   Sanders JM, Monogue ML, Jodlowski TZ, and Cutrell JB. Pharmacologic Treatments for
694   Coronavirus Disease 2019 (COVID-19): A Review. *JAMA.* 2020;323(18):1824-36.

695   2.   Lim ZJ, Subramaniam A, Ponnapa Reddy M, Blecher G, Kadam U, Afroz A, et al. Case
696   Fatality Rates for Patients with COVID-19 Requiring Invasive Mechanical Ventilation. A
697   Meta-analysis. *Am J Respir Crit Care Med.* 2021;203(1):54-66.

698   3.   Hull DL. *PSA: Proceedings of the biennial meeting of the philosophy of science association.*
699   Cambridge University Press; 1974:653-70.

700   4.   Te Pas MFW, Madsen O, Calus MPL, and Smits MA. The Importance of Endophenotypes
701   to Evaluate the Relationship between Genotype and External Phenotype. *International*
702   *Journal of Molecular Sciences.* 2017;18(2):472.

703   5.   Blatti III C, Emad A, Berry MJ, Gatzke L, Epstein M, Lanier D, et al. Knowledge-guided
704   analysis of "omics" data using the KnowEnG cloud platform. *PLoS biology.*
705   2020;18(1):e3000583.

706   6.   Emad A, Ray T, Jensen TW, Parat M, Natrajan R, Sinha S, et al. Superior breast cancer
707   metastasis risk stratification using an epithelial-mesenchymal-amoeboid transition gene
708   signature. *Breast Cancer Research.* 2020;22(1):74.

709   7.   Al-Hadrawi DS, Al-Rubaye HT, Almulla AF, Al-Hakeim HK, and Maes M. Lowered oxygen
710   saturation and increased body temperature in acute COVID-19 largely predict chronic
711   fatigue syndrome and affective symptoms due to Long COVID: A precision nomothetic
712   approach. *Acta Neuropsychiatr.* 2022:1-12.

713   8.   Tremblay K, Rousseau S, Zawati MnH, Auld D, Chassé M, Coderre D, et al. The Biobanque
714   québécoise de la COVID-19 (BQC19)—A cohort to prospectively study the clinical and
715   biological determinants of COVID-19 clinical trajectories. *PLoS one.* 2021;16(5):e0245031.

716   9.   Gold L, Ayers D, Bertino J, Bock C, Bock A, Brody E, et al. Aptamer-based multiplexed
717   proteomic technology for biomarker discovery. *Nature Precedings.* 2010:1-.

718   10.   Ward Jr JH. Hierarchical grouping to optimize an objective function. *Journal of the*
719   *American statistical association.* 1963;58(301):236-44.

720   11.   Murtagh F, and Legendre P. Ward's Hierarchical Agglomerative Clustering Method: Which
721   Algorithms Implement Ward's Criterion? *Journal of Classification.* 2014;31(3):274-95.

722   12.   Kaplan EL, and Meier P. Nonparametric Estimation from Incomplete Observations. *Journal*
723   *of the American Statistical Association.* 1958;53(282):457-81.

724   13.   Gillespie M, Jassal B, Stephan R, Milacic M, Rothfels K, Senff-Ribeiro A, et al. The reactome
725   pathway knowledgebase 2022. *Nucleic Acids Research.* 2021;50(D1):D687-D92.

726   14.   Blachier F, Andriamihaja M, and Blais A. Sulfur-Containing Amino Acids and Lipid
727   Metabolism. *The Journal of Nutrition.* 2020;150(Supplement_1):2524S-31S.

728   15.   Ye C, Sutter BM, Wang Y, Kuang Z, and Tu BP. A metabolic function for phospholipid and
729   histone methylation. *Molecular cell.* 2017;66(2):180-93. e8.

730   16.   Marfia G, Navone S, Guarnaccia L, Campanella R, Mondoni M, Locatelli M, et al. Decreased
731   serum level of sphingosine-1-phosphate: a novel predictor of clinical severity in COVID-
732   19. *EMBO molecular medicine.* 2021;13(1):e13424.

733   17.   Chen PY, Gao WY, Liou JW, Lin CY, Wu MJ, and Yen JH. Angiopoietin-Like Protein 3
734   (ANGPTL3) Modulates Lipoprotein Metabolism and Dyslipidemia. *Int J Mol Sci.*
735   2021;22(14).

736   18.   Lachkar F, Ferré P, Foufelle F, and Papaioannou A. Dihydroceramides: their emerging
737   physiological roles and functions in cancer and metabolic diseases. *American Journal of*
738   *Physiology-Endocrinology and Metabolism.* 2021;320(1):E122-E30.

739   19.   Lone MA, Hülsmeier AJ, Saied EM, Karsai G, Arenz C, von Eckardstein A, et al. Subunit
740   composition of the mammalian serine-palmitoyltransferase defines the spectrum of
741   straight and methyl-branched long-chain bases. *Proceedings of the National Academy of*
742   *Sciences.* 2020;117(27):15591-8.

743   20.   Han G, Gupta SD, Gable K, Niranjanakumari S, Moitra P, Eichler F, et al. Identification of
744   small subunits of mammalian serine palmitoyltransferase that confer distinct acyl-CoA
745   substrate specificities. *Proceedings of the National Academy of Sciences.*
746   2009;106(20):8186-91.

747   21.   Helms J, Tacquard C, Severac F, Leonard-Lorant I, Ohana M, Delabranche X, et al. High risk
748   of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective
749   cohort study. *Intensive Care Medicine.* 2020;46(6):1089-98.

750   22.   Asakura H, and Ogawa H. COVID-19-associated coagulopathy and disseminated
751   intravascular coagulation. *International Journal of Hematology.* 2021;113(1):45-57.

752   23.   Fahmy OH, Daas FM, Salunkhe V, Petrey JL, Cosar EF, Ramirez J, et al. Is Microthrombosis
753   the Main Pathology in Coronavirus Disease 2019 Severity?-A Systematic Review of the
754   Postmortem Pathologic Findings. *Crit Care Explor.* 2021;3(5):e0427.

755   24.   Barnes BJ, Adrover JM, Baxter-Stoltzfus A, Borczuk A, Cools-Lartigue J, Crawford JM, et al.
756   Targeting potential drivers of COVID-19: Neutrophil extracellular traps. *Journal of*
757   *Experimental Medicine.* 2020;217(6).

25. Bonaventura A, Vecchié A, Dagna L, Martinod K, Dixon DL, Van Tassell BW, et al.
Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-
19. *Nature Reviews Immunology.* 2021;21(5):319-29.

26. Ding J, Hostallero DE, El Khili MR, Fonseca GJ, Milette S, Noorah N, et al. A network-
informed analysis of SARS-CoV-2 and hemophagocytic lymphohistiocytosis genes'
interactions points to Neutrophil extracellular traps as mediators of thrombosis in COVID-
19. *PLoS Computational Biology.* 2021;17(3):e1008810.

27. Blasco A, Coronado M-J, Hernández-Terciado F, Martín P, Royuela A, Ramil E, et al.
Assessment of neutrophil extracellular traps in coronary thrombus of a case series of
patients with COVID-19 and myocardial infarction. *JAMA cardiology.* 2021;6(4):469-74.

28. Desilles JP, Solo Nomenjanahary M, Consoli A, Ollivier V, Faille D, Bourrienne MC, et al.
Impact of COVID-19 on thrombus composition and response to thrombolysis: Insights
from a monocentric cohort population of COVID-19 patients with acute ischemic stroke.
Journal of Thrombosis and Haemostasis. 2022;20(4):919-28.

29. Englert H, Rangaswamy C, Deppermann C, Sperhake J-P, Krisp C, Schreier D, et al.
Defective NET clearance contributes to sustained FXII activation in COVID-19-associated
pulmonary thrombo-inflammation. *EBioMedicine.* 2021;67:103382.

30. Leppkes M, Knopf J, Naschberger E, Lindemann A, Singh J, Herrmann I, et al. Vascular
occlusion by neutrophil extracellular traps in COVID-19. *EBioMedicine.* 2020;58:102925.

31. Middleton EA, He X-Y, Denorme F, Campbell RA, Ng D, Salvatore SP, et al. Neutrophil
extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory
distress syndrome. *Blood.* 2020;136(10):1169-79.

32. Obermayer A, Jakob L-M, Haslbauer JD, Matter MS, Tzankov A, and Stoiber W. Neutrophil
extracellular traps in fatal COVID-19-associated lung injury. *Disease markers.* 2021;2021.

33. Ouwendijk WJ, Raadsen MP, Van Kampen JJ, Verdijk RM, Von Der Thusen JH, Guo L, et al.
High levels of neutrophil extracellular traps persist in the lower respiratory tract of
critically ill patients with coronavirus disease 2019. *The Journal of infectious diseases.*
2021;223(9):1512-21.

34. Petito E, Falcinelli E, Paliani U, Cesari E, Vaudo G, Sebastiano M, et al. Association of
neutrophil activation, more than platelet activation, with thrombotic complications in
coronavirus disease 2019. *The Journal of infectious diseases.* 2021;223(6):933-44.

35. Skendros P, Mitsios A, Chrysanthopoulou A, Mastellos DC, Metallidis S, Rafailidis P, et al.
Complement and tissue factor–enriched neutrophil extracellular traps are key drivers in
COVID-19 immunothrombosis. *The Journal of clinical investigation.* 2020;130(11):6151-7.

36.   Massberg S, Grahl L, von Bruehl M-L, Manukyan D, Pfeiler S, Goosmann C, et al. Reciprocal
coupling of coagulation and innate immunity via neutrophil serine proteases. *Nature*
Medicine. 2010;16(8):887-96.

37.   Papayannopoulos V, Metzler KD, Hakkim A, and Zychlinsky A. Neutrophil elastase and
myeloperoxidase regulate the formation of neutrophil extracellular traps. *Journal of Cell*
Biology. 2010;191(3):677-91.

38.   Welin A, Amirbeagi F, Christenson K, Björkman L, Björnsdottir H, Forsman H, et al. The
Human Neutrophil Subsets Defined by the Presence or Absence of OLFM4 Both
Transmigrate into Tissue In Vivo and Give Rise to Distinct NETs In Vitro. *PLOS ONE.*
2013;8(7):e69575.

39.   Alder MN, Opoka AM, Lahni P, Hildeman DA, and Wong HR. Olfactomedin-4 Is a Candidate
Marker for a Pathogenic Neutrophil Subset in Septic Shock. *Critical Care Medicine.*
2017;45(4):e426-e32.

40.   Parman T, Bunin DI, Ng HH, McDunn JE, Wulff JE, Wang A, et al. Toxicogenomics and
metabolomics of pentamethylchromanol (PMCol)-induced hepatotoxicity. *Toxicological*
Sciences. 2011;124(2):487-501.

41.   Stafford JH, and Thorpe PE. Increased exposure of phosphatidylethanolamine on the
surface of tumor vascular endothelium. *Neoplasia.* 2011;13(4):299-IN2.

42.   Ran S, Downes A, and Thorpe PE. Increased exposure of anionic phospholipids on the
surface of tumor blood vessels. *Cancer research.* 2002;62(21):6132-40.

43.   Port JR, Adney DR, Schwarz B, Schulz JE, Sturdevant DE, Smith BJ, et al. High-fat high-sugar
diet-induced changes in the lipid metabolism are associated with mildly increased COVID-
19 severity and delayed recovery in the Syrian hamster. *Viruses.* 2021;13(12):2506.

44.   MacDonald J, and Sprecher H. Distribution of arachidonic acid in choline-and
ethanolamine-containing phosphoglycerides in subfractionated human neutrophils.
Journal of Biological Chemistry. 1989;264(30):17718-26.

45.   Papageorgiou C, Jourdi G, Adjambri E, Walborn A, Patel P, Fareed J, et al. Disseminated
intravascular coagulation: an update on pathogenesis, diagnosis, and therapeutic
strategies. *Clinical and Applied Thrombosis/Hemostasis.* 2018;24(9_suppl):8S-28S.

46.   Goligher EC, Bradbury CA, McVerry BJ, Lawler PR, Berger JS, Gong MN, et al. Therapeutic
Anticoagulation with Heparin in Critically Ill Patients with Covid-19. *N Engl J Med.*
2021;385(9):777-89.

47.   Lawler PR, Goligher EC, Berger JS, Neal MD, McVerry BJ, Nicolau JC, et al. Therapeutic
Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. *N Engl J Med.*
2021;385(9):790-802.

48.   Thomas T, Stefanoni D, Reisz JA, Nemkov T, Bertolone L, Francis RO, et al. COVID-19
828   infection alters kynurenine and fatty acid metabolism, correlating with IL-6 levels and
829   renal status. *JCI insight.* 2020;5(14).

830   49.   Zahedi K, Barone S, Kramer DL, Amlal H, Alhonen L, Jänne J, et al. The role of
831   spermidine/spermine N 1-acetyltransferase in endotoxin-induced acute kidney injury.
832   *American Journal of Physiology-Cell Physiology.* 2010;299(1):C164-C74.

833   50.   Pirnes-Karhu S, Jantunen E, Mäntymaa P, Mustjoki S, Alhonen L, and Uimari A.
834   Spermidine/spermine N1-acetyltransferase activity associates with white blood cell count
835   in myeloid leukemias. *Experimental Hematology.* 2014;42(7):574-80.

836   51.   Smadja DM, Philippe A, Bory O, Gendron N, Beauvais A, Gruest M, et al. Placental growth
837   factor level in plasma predicts COVID-19 severity and in-hospital mortality. *Journal of*
838   *Thrombosis and Haemostasis.* 2021;19(7):1823-30.

839   52.   Bussolari C, Palumbo D, Fominsky E, Nardelli P, De Lorenzo R, Vitali G, et al. Case Report:
840   Nintedaninb May Accelerate Lung Recovery in Critical Coronavirus Disease 2019. *Frontiers*
841   *in Medicine.* 2021;8:766486.

842   53.   Liu W, Peng Y, and Tobin DJ. A new 12-gene diagnostic biomarker signature of melanoma
843   revealed by integrated microarray analysis. *PeerJ.* 2013;1:e49.

844   54.   Luo S, Feofanova EV, Tin A, Tung S, Rhee EP, Coresh J, et al. Genome-wide association
845   study of serum metabolites in the African American Study of Kidney Disease and
846   Hypertension. *Kidney International.* 2021;100(2):430-9.

847   55.   Agarwal B, Gatt A, Riddell A, Wright G, Chowdary P, Jalan R, et al. Hemostasis in patients
848   with acute kidney injury secondary to acute liver failure. *Kidney International.*
849   2013;84(1):158-63.

850   56.   Williams R, Schalm SW, and O'Grady JG. Acute liver failure: redefining the syndromes. *The*
851   *Lancet.* 1993;342(8866):273-5.

852   57.   Koishi R, Ando Y, Ono M, Shimamura M, Yasumo H, Fujiwara T, et al. Angptl3 regulates
853   lipid metabolism in mice. *Nature Genetics.* 2002;30(2):151-7.

854   58.   Pisciotta L, Favari E, Magnolo L, Simonelli S, Adorni MP, Sallo R, et al. Characterization of
855   Three Kindreds With Familial Combined Hypolipidemia Caused by Loss-of-Function
856   Mutations of ANGPTL3. *Circulation: Cardiovascular Genetics.* 2012;5(1):42-50.

857   59.   Lekka ME, Liokatis S, Nathanail C, Galani V, and Nakos G. The Impact of Intravenous Fat
858   Emulsion Administration in Acute Lung Injury. *American Journal of Respiratory and Critical*
859   *Care Medicine.* 2004;169(5):638-44.

60.   Ahmad Z, Banerjee P, Hamon S, Chan K-C, Bouzelmat A, Sasiela WJ, et al. Inhibition of
Angiopoietin-Like Protein 3 With a Monoclonal Antibody Reduces Triglycerides in
Hypertriglyceridemia. *Circulation.* 2019;140(6):470-86.

61.   Bie H, Yin J, He X, Kermode AR, Goddard-Borger ED, Withers SG, et al. Insights into
mucopolysaccharidosis I from the structure and action of α-L-iduronidase. *Nature*
Chemical Biology. 2013;9(11):739-45.

62.   Ford L, Kennedy AD, Goodman KD, Pappan KL, Evans AM, Miller LAD, et al. Precision of a
Clinical Metabolomics Profiling Platform for Use in the Identification of Inborn Errors of
Metabolism. *The Journal of Applied Laboratory Medicine.* 2020;5(2):342-56.

63.   Durinck S, Spellman PT, Birney E, and Huber W. Mapping identifiers for the integration of
genomic datasets with the R/Bioconductor package biomaRt. *Nature Protocols.*
2009;4(8):1184-91.

64.   R Core Team. Vienna, Austria: R Foundation for Statistical Computing; 2022.
https://www.R-project.org/.

65.   Marees AT, de Kluiver H, Stringer S, Vorspan F, Curis E, Marie-Claire C, et al. A tutorial on
conducting genome-wide association studies: Quality control and statistical analysis. *Int J*
Methods Psychiatr Res. 2018;27(2):e1608.

66.   Ochoa A. genio: Genetics Input/Output Functions. 2022:R package version 1.1.1.
https://CRAN.R-project.org/package=genio.

67.   Warnes G, Gorjanc G, Leisch F, and Man M. genetics: Population Genetics. 2021:R package
version 1.3.8.1.3. https://CRAN.R-project.org/package=genetics.

68.   Zheng X, Levine D, Shen J, Gogarten SM, Laurie C, and Weir BS. A high-performance
computing toolset for relatedness and principal component analysis of SNP data.
Bioinformatics. 2012;28(24):3326-8.

69.   Perdry H, and Dandine-Roulland C. gaston: Genetic Data Handling (QC, GRM, LD, PCA) &
Linear Mixed Models. 2020:R package version 1.5.7. https://CRAN.R-
project.org/package=gaston.

70.   Satopaa V, Albrecht J, Irwin D, and Raghavan B. *2011 31st international conference on*
distributed computing systems workshops. IEEE; 2011:166-71.
889